Loading
Latest filing published 18 Sept 2026 for Knight Therapeutics Inc., €782. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Jonathan Ross Goodman on record concern Knight Therapeutics Inc. Over a trading history stretching from 15 June 2026 to 15 September 2026, the count stands at 4 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The record was last updated on 18 September 2026 with a share grant (€782) in Knight Therapeutics Inc. Filings reach the SEDI feed a median of 3 days after the trade. That lag is the time during which only the insider knows about the trade. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations